Blizard Institute - Barts and The London

Professor Borislava (Boby) Mihaylova, DPhil

Borislava (Boby)

Chair in Health Economics

Email: b.mihaylova@qmul.ac.uk
Telephone: 020 7882 3863

Profile

Borislava Mihaylova is a Professor of Health Economics at the Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London and leads the work of the health economics team at the Centre.

Borislava has wide ranging interests in health economic evaluation and health policy analyses with particular focus on cost-effectiveness analysis alongside clinical trials, evidence synthesis, heterogeneity in cost-effectiveness and statistical and epidemiologic methods in these areas. Her work on effectiveness and cost-effectiveness of statins for cardiovascular disease prevention has been highly influential in informing treatment recommendations for people at different vascular disease risk. 

Professor Mihaylova teaches at postgraduate, graduate and undergraduate levels and supervises students in her research areas.

Summary

Borislava was appointed to the Chair in Health Economics at the Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London in January 2018.  She also holds a part-time position of Associate Professor and Senior Health Economist at the University of Oxford's Health Economics Research Centre (HERC).

While studying BSc/MSc in Computer Sciences and Financial Technologies at the Technical University of Sofia, Bulgaria (1990-95), Borislava became involved in the development of the National Health Insurance system in Bulgaria. In 1993-9 she worked at the National Centre of Public Health and National Health Insurance Fund, Bulgaria on the design and implementation of case-mix payment methods for hospital care in Bulgaria. After completing her MSc in Health Economics at the University of York, UK (2000), she took a research post at the University of Southampton working on the health economic analyses of NHS Direct, the NHS out-of-hours system at the time, and growth hormone treatment in children and adults. In 2001-5 she completed a DPhil in Health Economics studying the cost-effectiveness of simvastatin in people at different cardiovascular disease risk in the 20,000-large Heart Protection Study guided by Professors Andrew Briggs, Rory Collins, Alastair Gray, Jane Armitage and Sarah Parish and supported by a NHS Training Fellowship. She continued her research work at the University of Oxford becoming University Research Lecturer in 2011 and Associate Professor in 2015.

Prof Mihaylova is a member of the NIHR Programme Grants for Applied Research (PGfAR) subpanel since June 2016.

Teaching

BSc Global Health, Queen Mary University of London

  • Introduction to health economics: module lead, lecturer, examiner

MSc in Global Health Science and Epidemiology, University of Oxford

  • Health Economics module: lecturer, examiner
  • MSc dissertation: supervisor, examiner 

DPhil in Population Health, University of Oxford

  • Supervisor

Research

Research Interests:

Professor Mihaylova’s research programme focuses on studying economic aspects of chronic diseases (eg,  respiratory health and asthma, mental health, cardiovascular, chronic kidney disease and diabetes) and interventions and comprises studies of the impact of diseases and interventions on morbidity, mortality, health-related quality of life and healthcare costs; development of disease models to evaluate long-term effects of diseases and interventions, cost-effectiveness analyses of healthcare interventions and studies of socio-economic determinants of health. She leads the development of the economic analyses of policies and treatments studied a number of large randomised (SCENE, SHARP, THRIVE, REVEAL and ACST-2) and non-randomised (ULEZ) controlled studies, and in the individual participant data meta-analysis of statin trials (Cholesterol Treatment Collaboration). Her goal is to generate evidence that reliably informs national and international health policy and improves population health.

Professor Mihaylova leads the Health Economics Research Team.

Current Health Economics Research Team Members:

Dr Sergi Alonso, Health Economist

Dr Vladimir Gordeev, Senior Health Economist 

Dr Yan Feng, Senior Lecturer in Health Economics

Chris Roukas, Health Economist

Dr Florian Tomini, Lecturer in Health Economics

Previous Health Economics Research Team Members:

Dr Vladislav Berdunov

Dr Natalia Hounsome

Research Groups:

Centre for Primary Care and Public Health, QMUL
Pragmatic Clinical Trials Unit, QMUL
Asthma UK Centre for Applied Research, QMUL
Nuffield Department of Population Health, University of Oxford
Health Economics Research Centre, University of Oxford

 

Publications

Key Publications:

Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, Wanner C, Fellström B, Gray A, Landray MJ, Baigent C, Mihaylova B on behalf of the SHARP Collaborative Group. A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart 2017;103:1880-1890.

Kent S, Green J, Reeves G, Beral V, Gray A, Jebb SA, Cairns BJ*, Mihaylova B*, on behalf of the Million Women Study collaborators. Hospital costs in relation to body mass index in 1.1 million women in England: a prospective cohort study. Lancet Public Health. 2017. 2: e214–22.

Cholesterol Treatment Trialists’ (CTT) Collaboration (Writing committee: W Herrington*, J Emberson*, B Mihaylova*, L Blackwell, C Reith, M D Solbu, P B Mark, B Fellström, A G Jardine, C Wanner, H Holdaas, J Fulcher, R Haynes, M J Landray, A Keech, J Simes, R Collins, C Baigent). Impact of renal function on the effects of reducing LDL cholesterol with statin-based regimens: meta-analysis of individual data from 28 randomised trials. Lancet Diabetes and Endocrinology. 2016; 4: 829–39.

Kent S, Haynes R, Hopewell J, Parish S, Gray A, Landray M J, Collins R, Armitage J, Mihaylova B on behalf of the HPS2-THRIVE Collaborative Group. The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs. Circulation: Cardiovascular Quality and Outcomes. 2016; 9:348-354.

Mihaylova B, Schlackow I, Herrington W, Lozano-Kühne J, Kent S, Emberson J, Reith C, Haynes R, Cass A, Craig J, Gray A, Collins R, Landray M, Baigent C. Cost-effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).  American Journal of Kidney Diseases. 2016; 67(4): 576-584.

Cholesterol Treatment Trialists’ (CTT) Collaborators (Writing Committee: Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes E H, Voysey M, Gray A, Collins R, and Baigent C). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380(9841):581-90.

Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Economics 2011;20(8):897-916.

Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R on behalf of the Heart Protection Study Collaborative Group. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 2006;333:1145-8.

Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R on behalf of the Heart Protection Study Collaborative Group. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet 2005;365:1779-85.

 

All publications:

 

  • O'Halloran R, Mihaylova B, Cairns BJ et al. (2020). BMI and Cause-Specific Hospital Admissions and Costs: The UK Biobank Cohort Study.. nameOfConference


    QMRO: qmroHref
  • Levy M, Chen Y, Clarke R et al. (2020). Socioeconomic differences in health-care use and outcomes for stroke and ischaemic heart disease in China during 2009–16: a prospective cohort study of 0·5 million adults. nameOfConference


    QMRO: qmroHref
  • Mach F, Baigent C, Catapano AL et al. (2020). Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). nameOfConference


    QMRO: qmroHref
  • Mach F, Baigent C, Catapano AL et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. nameOfConference


  • Mach F, Baigent C, Catapano AL et al. (2020). 2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk (vol 290, pg 140, 2019). nameOfConference


    QMRO: qmroHref
  • Keng MJ, Tsiachristas A, Leal J et al. (2019). Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs. nameOfConference


  • Levy M, Chen Y, Clarke R et al. (2019). Declining socioeconomic inequalities in hospital care use and case fatality rates for stroke and ischaemic heart disease in China during 2009-16: a prospective study of 0.5 million adults. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Thorn J, Davies CF, Brookes ST et al. (2019). Essential items for a Health Economics Analysis Plan (HEAP): expert Delphi consensus survey. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Oke JL, Feakins BG, Schlackow I et al. (publicationYear). Statistical models for the deterioration of kidney function in a primary care population: A retrospective database analysis. nameOfConference


    QMRO: qmroHref
  • Hopewell JC, Ibrahim M, Hill M et al. (2019). Impact of ADCY9 Genotype on Response to Anacetrapib.. nameOfConference


    QMRO: qmroHref
  • Schlackow I, Kent S, Herrington W et al. (2019). Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.. nameOfConference


  • Schlackow I, Kent S, Herrington W et al. (publicationYear). Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. nameOfConference


  • Edwards MR, Forbes G, MacDonald N et al. (2019). Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac output-guided fluid therapy with low-dose inotrope infusion compared with usual care in patients undergoing major elective gastrointestinal surgery.. nameOfConference


  • Keng MJ, Tsiachristas A, Leal J et al. (2019). Impact of variation in Type 2 diabetes care on health outcomes and healthcare costs. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Kent S, Aveyard P, Astbury N et al. (2019). Is Doctor Referral to a Low-Energy Total Diet Replacement Program Cost-Effective for the Routine Treatment of Obesity?. nameOfConference


  • MIHAYLOVA BA (2019). Efficacy and safety of statin therapy in older people: meta-analysis of individual participant data from 28 randomised controlled trials. nameOfConference


  • Kent S, Jebb S, Gray A et al. (2018). Body Mass Index and use and costs of primary care services among women aged 55 to 79 years in England: a cohort and linked data study. nameOfConference


  • Castellani J, Mihaylova B, Siribié M et al. (2018). Household costs and time to treatment for children with severe febrile illness in rural Burkina Faso: The role of rectal artesunate 11 Medical and Health Sciences 1103 Clinical Sciences. nameOfConference


  • Herrington WG, Donovan K, Mihaylova B (2018). Authors’ reply. nameOfConference


  • Mihaylova B, Collaborative HT-R (2018). Assessing cardiovascular risk in people with atherosclerotic vascular disease on intensive statin therapy. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Jepson M, Elliott D, Conefrey C et al. (2018). An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. nameOfConference


  • Marthi A, Donovan K, Haynes R et al. (2018). Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. nameOfConference


  • Lokuge K, de Waard DD, Halliday A et al. (2018). Meta-Analysis of the Procedural Risks of Carotid Endarterectomy and Carotid Artery Stenting Over Time. nameOfConference


    QMRO: qmroHref
  • Morton RL, Schlackow I, Gray A et al. (2018). Impact of CKD on Household Income. nameOfConference


  • Lokuge K, de Waard DD, Halliday A et al. (2018). Meta-analysis of the procedural risks of carotid endarterectomy and carotid artery stenting over time. nameOfConference


  • Schlackow I, Kent S, Herrington W et al. (2017). A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. nameOfConference


  • Bowman L, Hopewell JC, Chen F et al. (2017). Effects of anacetrapib in patients with atherosclerotic vascular disease. nameOfConference


  • Kent S, Fusco F, Gray A et al. (2017). Body mass index and healthcare costs: a systematic literature review of individual participant data studies. nameOfConference


  • Clayton GL, Smith IL, Higgins JPT et al. (2017). The INVEST project: Investigating the use of evidence synthesis in the design and analysis of clinical trials. nameOfConference


  • Schlackow I, Mihaylova B, Grp SHARPC (2017). A lifetime disease model based on an RCT: development, validation and applications. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Thorn J, Ridyard C, Hughes D et al. (2017). Health economics analysis plans: the current state of play. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Schlackow I, Gray A, Sharples L et al. (2017). Methods for extrapolation from clinical trial data to inform economic evaluations: a taxonomy. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • de Waard DD, Halliday A, de Borst GJ et al. (2017). Choices of Stent and Cerebral Protection in the Ongoing ACST-2 Trial: A Descriptive Study.. nameOfConference


  • Kent S, Green J, Reeves G et al. (2017). Hospital costs in relation to body-mass index in 1·1 million women in England: a prospective cohort study. nameOfConference


  • Bowman L, Chen F, Sammons E et al. (2017). Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. nameOfConference


  • Achelrod D, Gray A, Preiss D et al. (2017). Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe. nameOfConference


  • Herrington WG, Emberson J, Mihaylova B et al. (2016). Are statins useful in patients with advanced chronic kidney disease? – Authors' reply. nameOfConference


  • Thorn JC, Ridyard CH, Hughes D et al. (2016). HEALTH ECONOMICS ANALYSIS PLANS: WHERE ARE WE NOW?. nameOfConference


  • Lokuge K, de Waard D, Bulbulia R et al. (2016). Procedural risks of carotid endarterectomy and carotid artery stenting have improved since 2005: Results from a systematic review of observational studies. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Herrington WG, Emberson J, Mihaylova B et al. (2016). Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. nameOfConference


  • Kent S, Haynes R, Hopewell JC et al. (2016). Effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs. nameOfConference


  • Reith C, Blackwell L, Emberson J et al. (2016). Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. nameOfConference


    QMRO: qmroHref
  • Mihaylova B, Schlackow I, Herrington W et al. (2016). Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: Results of the study of heart and renal protection (SHARP). nameOfConference


    QMRO: qmroHref
  • Morton RL, Schlackow I, Staplin N et al. (2016). Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. nameOfConference


    QMRO: qmroHref
  • Castellani J, Nsungwa-Sabiiti J, Mihaylova B et al. (2016). Impact of improving community-based access to malaria diagnosis and treatment on household costs. nameOfConference


  • Castellani J, Mihaylova B, Ajayi IO et al. (2016). Quantifying and valuing community healthworker time in improving access to malaria diagnosis and treatment. nameOfConference


  • Morton RL, Schlackow I, Mihaylova B et al. (2016). The impact of social disadvantage in moderate-to-severe chronic kidney disease: An equity-focused systematic review. nameOfConference


    QMRO: qmroHref
  • Lokuge K, Halliday A, Bulbulia R et al. (2015). Systematic review of randomised and observational evidence of effects of treatments of carotid stenosis to prevent stroke. nameOfConference


    QMRO: qmroHref
  • Castellani J, Mihaylova B, Evers SMAA et al. (2015). Out-of-Pocket Costs and Other Determinants of Access to Healthcare for Children with Febrile Illnesses: A Case-Control Study in Rural Tanzania (vol 10, 0122386, 2015). nameOfConference


    QMRO: qmroHref
  • Morton RL, Schlackow I, Staplin N et al. (2015). IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE. nameOfConference


    QMRO: qmroHref
  • Kent S, Schlackow I, Lozano-Kühne J et al. (2015). What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. nameOfConference


    QMRO: qmroHref
  • Castellani J, Mihaylova B, Evers SMAA et al. (2015). Out-of-pocket costs and other determinants of access to healthcare for children with febrile illnesses: A case-control study in rural Tanzania. nameOfConference


    QMRO: qmroHref
  • Alva ML, Gray A, Mihaylova B et al. (2015). The impact of diabetes-related complications on healthcare costs: New results from the UKPDS (UKPDS 84). nameOfConference


    QMRO: qmroHref
  • Fulcher J, O'Connell R, Voysey M et al. (2015). Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials. nameOfConference


    QMRO: qmroHref
  • Lokuge K, Halliday A, Bulbulia R et al. (2015). Systematic review of randomised and observational evidence of effects of treatments of carotid stenosis to prevent stroke.. nameOfConference


    QMRO: qmroHref
  • Alva M, Gray A, Mihaylova B et al. (2014). The effect of diabetes complications on health-related quality of life: The importance of longitudinal data to address patient heterogeneity. nameOfConference


    QMRO: qmroHref
  • Schlackow I, Mihaylova B (2013). Developing a lifetime disease model from RCT data using parametric models with time-updated covariates.. nameOfConference


    QMRO: qmroHref
  • Halliday A, Bulbulia R, Gray W et al. (2013). Status update and interim results from the asymptomatic carotid surgery trial-2 (ACST-2). nameOfConference


    QMRO: qmroHref
  • Mihaylova B, Emberson J, Keech A et al. (2012). Authors' reply. nameOfConference


    QMRO: qmroHref
  • Mihaylova B, Emberson J, Blackwell L et al. (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. nameOfConference


    QMRO: qmroHref
  • Mihaylova B, Briggs A, O'Hagan A et al. (2011). Review of statistical methods for analysing healthcare resources and costs. nameOfConference


    QMRO: qmroHref
  • Alva M, Gray AM, Mihaylova B et al. (2011). Outpatient Resource Utilization of Type-2 Diabetes Patients: New Evidence from the UKPDS. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Alva ML, Gray A, Mihaylova B et al. (2011). The effect of diabetes complications on health-related quality of life: estimating the bias due to unobserved heterogeneity using the UKPDS.. nameOfConference


    QMRO: qmroHref
  • Buchanan J, Mihaylova B, Gray A et al. (2010). Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness. nameOfConference


    QMRO: qmroHref
  • Maude RJ, Mihaylova B, Warsame M et al. (2010). RECTAL AND INTRAVENOUS ARTESUNATE FOR SEVERE MALARIA: MODELLING THE IMPACT OF ARTEMISININ RESISTANCE. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Alva ML, Gray A, Mihaylova B et al. (2010). Estimating the quality of life impact of diabetes related complications: new results from the UKPDS. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Mihaylova B, Pitman R, Tincello D et al. (2010). Cost-effectiveness of duloxetine: The stress urinary incontinence treatment (SUIT) study. nameOfConference


    QMRO: qmroHref
  • Mihaylova B, Briggs A, Hlatky M et al. (2009). Statin cost-effectiveness in the United States for people at different vascular risk levels. nameOfConference


    QMRO: qmroHref
  • Briggs A, Mihaylova B, Sculpher M et al. (2007). Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. nameOfConference


    QMRO: qmroHref
  • Mihaylova B, Briggs A, Armitage J et al. (2006). Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from randomised trial of 20 536 people. nameOfConference


    QMRO: qmroHref
  • Briggs A, Mihaylova B, Sculpher M et al. (2006). The cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Briggs A, Mihaylova B, Sculpher M et al. (2006). The cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Mihaylova B, Armitage J, Briggs A et al. (2005). Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Mihaylova B, Briggs A, Armitage J et al. (2005). Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: Economic analysis of a randomised trial in 20 536 individuals. nameOfConference


    QMRO: qmroHref
  • Briggs A, Armitage J, Gray A et al. (2003). Economic evaluation of the Heart Protection Study. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Bryant J, Loveman E, Chase D et al. (2002). Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: A systematic review and economic evaluation. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Bryant J, Cave C, Mihaylova B et al. (2002). Clinical effectiveness and cost-effectiveness of growth hormone in children: A systematic review and economic evaluation. nameOfConference


    QMRO: qmroHref